Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

Since becoming Vertex's top scientist in 2015, Altshuler has shaped the company’s efforts to expand beyond cystic fibrosis.

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...